

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): **October 8, 2021**

Assure Holdings Corp.

(Exact name of registrant as specified in its charter)

Nevada	001-40785	82-2726719
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4600 South Ulster Street, Suite 1225 Denver, CO		80237
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: **720-287-3093**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: **None**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD

On October 8, 2021, Assure Holdings Corp. issued a press release announcing Assure has performed its first neuromonitoring case in the state of Nevada. A copy of the press release is attached to this report as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this report shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Exhibits**Exhibit No. Name**

99.1	Press Release dated October 8, 2021
104	Cover Page Interactive Data File (formatted in Inline XBRL and included as Exhibit 101).



4600 S. Ulster Street
Suite 1225
Denver, CO 80237
(720)287-3093

Assure Holdings Expands Operational Footprint With First Neuromonitoring Case in Nevada

Company Begins Providing Services in Twelfth State

DENVER, October 8, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the **Company** or **Assure**) (NASDAQ: IONM; TSXV: IOM), a provider of intraoperative neuromonitoring services ("**IONM**"), is pleased to announce that it has performed its first neuromonitoring case in Nevada and has signed an agreement to provide IONM services for eight hospitals in the state, primarily in the Las Vegas metro area.

"We expect to grow rapidly in Nevada and are confident in our ability to take advantage of sizeable business development opportunities in the state," said John A. Farlinger, Assure's executive chairman and CEO. "On a per capita basis, Las Vegas is among the largest spine surgery markets in the nation. Over the next year, we anticipate that Nevada will be among Assure's fastest growing markets."

Assure will begin working with five surgeons that specialize in neurosurgery and orthopedic spine surgery. These surgeons perform approximately 2,000 procedures annually. Assure anticipates that the number of surgeons it provides service to in Nevada will expand in the future.

Over the past three years, Assure has expanded beyond its home base of Colorado and is now operating in twelve states: Texas, Louisiana, Utah, Pennsylvania, Michigan, South Carolina, Arizona, Kansas, Missouri, Nebraska and Nevada. This growth has been driven by the Company's reputation for providing exceptional quality of service and unique clinical expertise. An additional driver to the Company's growth is the increase in demand for neuromonitoring services across numerous medical procedures.

About Assure Holdings

Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commission's Gold Seal of Approval®. For more information, visit the company's website at www.assureneuromonitoring.com.



4600 S. Ulster Street
Suite 1225
Denver, CO 80237
(720)287-3093

Forward-Looking Statements

This news release may contain "forward-looking statements" within the meaning of applicable securities laws, including, but not limited to: the Company's growth plans; the Company's reputation in the IONM industry; the effects of the Company's expansion into Texas and the Company's ability to take advantage of expansion opportunities in the United States. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variation or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company's operations and economic activity in general; that the Company's actions taken during the COVID-19 health crisis will be effective;; the Company's ability to take advantage of expansion and business development opportunities in Texas and the United States; the Company may not expand into new states or extend its reach within its current operational footprint; the demand for the Company's for neuromonitoring services may not continue to increase; the Company may not maintain its strong reputation in the IONM industry; the Company's new Texas partners may not continue to perform more than 400 procedures annually; the Company may not continue seeing positive impact from its medical device distributor outreach; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company's profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-287-3093
Scott.Kozak@assureiom.com
